Limited Manufacture of Guinea-Variant Ebola Therapeutic by Tekmira Pharma

Ebola Guinea Variant is the viral variant which is responsible for the Ebola epidemic in West Africa.Tekmira Pharma has designed modified RNAi therapeutic specifically targeting Ebola Guinea and has limited the GMP manufacture of this modified RNAi.

The company will start the supply of this product in early December 2014 for use by various collaborators. Tekmira Pharma has collaborated with the international consortium led by the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), the University of Oxford, with representatives from the WHO, the US Centre for Disease Control (CDC), Medecins Sans Frontieres (MSF), Institut Pasteur and others, on plans for potential expedited clinical trials in West Africa.

An award of euro 3.2 million has been granted by the Wellcome trust which includes funds for the manufacture of investigational therapeutics and to establish an operational clinical trials platform in two or more Ebola Virus Disease (EVD) treatment centers in West Africa. RNA i therapeutics developed by Tekmira Pharma has been prioritized in this initiative however the news has not yet been confirmed.

FDA has authorized Tekmira Pharma previously to provide the TKM-Ebola to patients with suspected or confirmed Ebola virus infections. Although the inventory is limited Tekmira will provide the TKM-Ebola on request to patients with confirmed or suspected Ebola virus infection under FDA regulatory Framework.